CL2017000378A1 - Métodos para tratar la depresión usando moduladores de nmda - Google Patents

Métodos para tratar la depresión usando moduladores de nmda

Info

Publication number
CL2017000378A1
CL2017000378A1 CL2017000378A CL2017000378A CL2017000378A1 CL 2017000378 A1 CL2017000378 A1 CL 2017000378A1 CL 2017000378 A CL2017000378 A CL 2017000378A CL 2017000378 A CL2017000378 A CL 2017000378A CL 2017000378 A1 CL2017000378 A1 CL 2017000378A1
Authority
CL
Chile
Prior art keywords
methods
treat depression
nmda modulators
depression
nmda
Prior art date
Application number
CL2017000378A
Other languages
English (en)
Inventor
Ron Burch
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of CL2017000378A1 publication Critical patent/CL2017000378A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>LA PRESENTE DESCRIPCIÓN PROPORCIONA MÉTODOS Y REGÍMENES PARA TRATAR LA DEPRESIÓN (POR EJEMPLO, DEPRESIÓN RESISTENTE AL TRATAMIENTO) EN UN PACIENTE (POR EJEMPLO, UN PACIENTE QUE NECESITA DICHO TRATAMIENTO).</p>
CL2017000378A 2014-08-14 2017-02-14 Métodos para tratar la depresión usando moduladores de nmda CL2017000378A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14

Publications (1)

Publication Number Publication Date
CL2017000378A1 true CL2017000378A1 (es) 2017-11-03

Family

ID=55304631

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000378A CL2017000378A1 (es) 2014-08-14 2017-02-14 Métodos para tratar la depresión usando moduladores de nmda

Country Status (18)

Country Link
US (1) US20170296616A1 (es)
EP (1) EP3180015A4 (es)
JP (2) JP2017524721A (es)
KR (1) KR20170040351A (es)
CN (1) CN106659763A (es)
AU (2) AU2015301650A1 (es)
BR (1) BR112017002930A2 (es)
CA (1) CA2957937A1 (es)
CL (1) CL2017000378A1 (es)
CO (1) CO2017002356A2 (es)
IL (1) IL250557A0 (es)
MX (1) MX2017002052A (es)
PH (1) PH12017500275A1 (es)
RU (1) RU2017107033A (es)
SG (2) SG11201701134XA (es)
UA (1) UA123623C2 (es)
WO (1) WO2016025721A1 (es)
ZA (1) ZA201701526B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530593A (ja) * 2015-10-16 2018-10-18 ノースウェスタン ユニバーシティ 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
JP2021512857A (ja) * 2017-11-10 2021-05-20 ノーレックス インコーポレイテッド Ｎｍｄａ受容体アゴニストの投与方法
CA3084437A1 (en) 2017-12-05 2019-06-13 Naurex Inc. Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2485751T3 (pl) * 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Also Published As

Publication number Publication date
UA123623C2 (uk) 2021-05-05
IL250557A0 (en) 2017-03-30
JP2017524721A (ja) 2017-08-31
JP2020128391A (ja) 2020-08-27
PH12017500275A1 (en) 2017-07-03
EP3180015A4 (en) 2018-02-14
EP3180015A1 (en) 2017-06-21
US20170296616A1 (en) 2017-10-19
KR20170040351A (ko) 2017-04-12
MX2017002052A (es) 2018-08-15
AU2020203165A1 (en) 2020-06-04
BR112017002930A2 (pt) 2017-12-05
CN106659763A (zh) 2017-05-10
RU2017107033A (ru) 2018-09-14
WO2016025721A1 (en) 2016-02-18
RU2017107033A3 (es) 2019-02-12
CA2957937A1 (en) 2016-02-18
ZA201701526B (en) 2018-05-30
AU2015301650A1 (en) 2017-03-23
SG10201810016XA (en) 2018-12-28
SG11201701134XA (en) 2017-03-30
CO2017002356A2 (es) 2017-06-09

Similar Documents

Publication Publication Date Title
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
ECSP17029218A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MX2016010293A (es) Micro-organoides, y metodos de fabricacion y usos los mismos.
ECSP16081503A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
MX387159B (es) Moléculas basadas en il-15 y métodos para su uso.
BR112016018313A2 (pt) moléculas de ligação multiespecíficas iga
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
PE20180260A1 (es) Metodos y kits para tratar la depresion
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX384909B (es) Un anticuerpo anti-tau para usarse al tratar una tauopatía.
SG10201900574SA (en) Virtual currency conversion device, method and computer program
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112015022604A2 (pt) usos de um modulador de modificador de cromatina e um antagonista de egfr
CL2017000378A1 (es) Métodos para tratar la depresión usando moduladores de nmda
ECSP13013081A (es) Inducción de tolerancia inmunológica utilizando metotrexato
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
MX2018008407A (es) Dispositivo secundario.
CL2016002754A1 (es) Dispositivo de tratamiento y procedimiento de tratamiento para el decapado y fosfatado de piezas de metal
UY36602A (es) Variantes de protoxina-ii y métodos de uso
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
MX2020011946A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer